Glaxosmithkline (GSK)


GSK Share PerformanceMore

52 week high1,724.5 22/06/17
52 week low1,236.5 06/02/18
52 week change -390.0 (-23.12%)
4 week volume172,856,147 22/02/18
price date1521571145

Latest NewsMore

GSK 2017 Form 20-F

RNS Number: 0605I GlaxoSmithKline PLC 16 March 2018 Issued: 16 March 2018 London UK - LSE Announcement GlaxoSmithKline plc Annual Report 2017 on Form 20-F In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GlaxoSmithKline plc ("GSK") announces that on 16 March 2018 it filed with the Securities and Exchan...

Broker Forecast - Societe Generale issues a broker note on GlaxoSmithKline PLC

Societe Generale today reaffirms its sell investment rating on GlaxoSmithKline PLC (LON:GSK) and set its price target at 1...

Annual Financial Report

RNS Number: 5943H GlaxoSmithKline PLC 13 March 2018 GlaxoSmithKline plc (the 'Company') Publication of 2017 Annual Report The Company will today publish on its website, , the Annual Report for the year ended 31 December 2017 (the '2017 Annual Report'). A hard copy version of the following documents will be sent to those share...

Director/PDMR Shareholding

RNS Number: 4695H GlaxoSmithKline PLC 12 March 2018 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Ms E Walmsley b) Position/status Chief Executive Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participan...

GSK announces labelling update to Relvar Ellipta

RNS Number: 0866H GlaxoSmithKline PLC 08 March 2018 Issued: 8 March 2018 London UK - LSE Announcement GSK announces positive EU approval for labelling update to Relvar Ellipta in patients with asthma GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has approved a label upd...

ViiV Healthcare announces new dolutegravir data

RNS Number: 7502G GlaxoSmithKline PLC 05 March 2018 Issued: 5 March 2018, London UK - LSE Announcement ViiV Healthcare announces positive new dolutegravir data for the treatment of people living with HIV co-infected with tuberculosis INSPIRING study results contribute to the extensive body of evidence for dolutegravir, the leading integrase strand tra...

GlaxoSmithKline presents positive study results for asthma treatment

GlaxoSmithKline said it had presented positive results from a study at a gathering in Orlando that showed patients who sw...

Nucala OSMO study presented at AAAAI-WAO congress

RNS Number: 7283G GlaxoSmithKline PLC 05 March 2018 Issued 5 th March 2018, London UK - LSE Announcement Nucala (mepolizumab) improved asthma control in patients uncontrolled on Xolair (omalizumab) Positive clinical study outcomes observed for severe eosinophilic asthma patients uncontrolled on omalizumab when switched to mepolizumab in an ...

Fundamental DataMore

P/E ratio69.011
Dividend yield6.166 %

Latest discussion posts More

  • Re: Trump Drug Pricing Plans

    "Anybody know more about Trumps plans (on drug pricing plans)" I saw him saying in a speech yesterday that he's ready to execute drug dealers. I hope that doesn't include ...
  • Trump Drug Pricing Plans

    Hi All, Heard part of a piece on the news yesterday that Trump plans to unveil his drug pricing plans shortly. Previously I think that he had stated that he wanted to ...
  • Generic delay

    "Vectura was down 4.4% on news it, along with partner Hikma Pharmaceuticals, will be required to conduct an additional clinical endpoint study for the development of a generic ...
    Lupo di mare

Users' HoldingsMore

Users who hold Glaxosmithkline also hold..
3I INF. ORD25%

Codes & Symbols